Alligator Bioscience AB

ATORX · Nasdaq Stockholm · Healthcare

0.02SEK −2.0%last day

Price as of 2 October 2026

The price over the past year, with dividends: −97.8%

Performance

1 month

−24.9%

1 year

−97.8%

3 years, per year

−85.7%

5 years, per year

−77.4%

Largest fall, 3 years

−99.9%

Below the peak now

−100.0%

Volatility, 1 year

175.5%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

3.5

Dividend yield

0.0%

Return on equity

−100.7%

Net margin

−163.6%

Market value

1 m USD

Quality, value and trend

Where Alligator Bioscience stands against every Nordic stock today. 100 is best.

Quality26

Profitability and a sound balance sheet over time. Better than 26% of Nordic stocks.

Value8

The price measured against earnings, assets and cash flow. Better than 8% of Nordic stocks.

Trend0

The price development over the past year. Better than 0% of Nordic stocks.

Combined1

Quality, value and trend together. Better than 1% of Nordic stocks.

About Alligator Bioscience

Alligator Bioscience AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 11 employees.

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Belgium. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 3 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis